MagSense Nanoparticle Manufacturing Update
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Imagion Biosystems Ltd. has announced the resumption of its MagSense® nanoparticle manufacturing capabilities through a partnership with a Contract Development and Manufacturing Organisation. This agreement aims to align manufacturing processes with U.S. FDA quality requirements and supports the company's strategic business plan. The MagSense® technology is designed to enhance cancer detection using non-radioactive magnetic nanoparticles, improving diagnostic precision.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Imagion Biosystems Ltd. on 6ix
Earlier from Imagion Biosystems
- IBX Phase 2 Clinical Trial Update
- Appendix 4C and Quarterly Activities Report - June 2026
- Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial
- IBX Secures Firm Commitments for $3.75m for Clinical Trial
- Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
Later from Imagion Biosystems
- Imagion Resumes MagSense® Nanoparticle Manufacturing Capabilities
- IBX Secures Central Ethics Approval - Key Phase 2 Milestone
- Appendix 4C and Quarterly Activities Report - September 2026
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems